Regulatory Strategy & Global Submissions
Regulatory strategy is not a documentation exercise. It is an enterprise risk decision that directly affects timelines, valuation, and market access.
SHOTUNE provides founder-led regulatory leadership to medical device (Class I-III) companies navigating FDA, EU-MDR and global approval pathways where the cost of getting it wrong is no longer acceptable.
A confidential discussion to assess regulatory risk, strategic options, and next steps.
What This Protects
Approval timelines
Market access strategy
Valuation and diligence readiness
Execution confidence under regulator scrutiny
Regulatory decisions made too late create rework. Regulatory decisions made early protect enterprise value.
Escalate Regulatory Strategy When
- Submission logic is unclear or difficult to defend
- FDA or Notified Body feedback is exposing deeper strategic gaps
- Internal teams need senior judgment on pathway, claims, or response posture
- Leadership needs clarity before a major submission, remediation, or market expansion
- Regulatory uncertainty is beginning to affect business confidence
Escalation restores clarity before exposure becomes material.
Why Companies Escalate to SHOTUNE
- Large consulting firms often provide scale, but accountability is diluted
- Former regulators may offer interpretation, but not execution ownership
- Internal teams and contractors may provide support, but not senior judgment under ambiguity
SHOTUNE is engaged when regulatory decisions cannot be delegated and the business consequences
of delay, rework, or misalignment are no longer acceptable.
Strategic Scope
FDA, EU MDR, and global
pathway strategy
classification, predicate, and pathway positioning
Regulatory response and change governance
Inspection and diligence defense
How We Work
Operates as embedded executive leadership, not a document vendor:
We begin by identifying where the true regulatory risk sits—not only in the submission itself, but across evidence, claims, quality alignment, and execution posture.
From there, SHOTUNE works with leadership and internal teams to clarify the regulator-facing narrative, reduce uncertainty, and establish a path forward that is both defensible and commercially realistic.
What an Initial Regulatory Engagement May Include
- Assessment of pathway, submission, or response risk
- Clarification of regulator-facing narrative and decision logic
- Identification of strategic gaps driving rework or delay
- Prioritized next steps for leadership, internal teams, and external stakeholders
Founder Accountability
- Every regulatory engagement is personally led by Shola Sulaimon. SHOTUNE does not delegate high-stakes strategy to junior teams.
- Clients receive direct executive-level judgment designed to reduce regulatory uncertainty before it becomes operational exposure.
FAQs
1. We have a stalled FDA or CE Mark submission. Can SHOTUNE step in midstream?
Yes. For startups, that often means correcting a pathway or evidence problem before valuable time and capital are lost. For growth-stage and larger organizations, it often means stabilizing a submission that is already drawing repeated objections, internal rework, or executive concern.
2. Our pathway, classification, or predicate is still unclear. Can SHOTUNE help us decide before we lose time?
Yes. Early regulatory ambiguity is expensive for smaller companies because it delays development decisions and investor milestones. For scaling and established manufacturers, it can create downstream claims, evidence, and portfolio planning problems that are much harder to unwind later.
3. FDA or our Notified Body feedback keeps escalating unpredictably. How does SHOTUNE help?
Escalating feedback usually means the issue is not just the response letter. It is a deeper misalignment between pathway, evidence, claims, and risk logic. SHOTUNE helps leadership reframe the strategy, strengthen the regulator-facing narrative, and reduce further review-cycle erosion.
4. Do you engage directly with FDA and Notified Bodies?
Yes. SHOTUNE supports pre-submission strategy, formal interactions, responses to questions, and escalation planning. For lean teams, that brings needed senior leadership into critical moments. For larger teams, it provides higher-level strategic control when internal bandwidth or alignment is strained.
5. How is SHOTUNE different from traditional regulatory consulting firms?
SHOTUNE is founder-led, judgment-driven, and directly accountable. That matters whether you are a startup that cannot afford avoidable missteps, a scaling company trying to commercialize with confidence, or a larger manufacturer that needs senior regulatory leadership rather than more document throughput.
6. Can SHOTUNE help if prior advice has already led to rework or lost momentum?
Yes. That is often when SHOTUNE is engaged. We assess what is salvageable, identify where the strategy broke down, and help your team move forward with clearer decisions and stronger regulator alignment.